Tag Archives: Says

AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder.  The Institute for Clinical and… Read More »

Rise in adolescent Covid hospitalizations is reflection of new variants, Gottlieb says

Dr. Scott Gottlieb pointed on Friday to the highly transmissible Covid-19 variants as a potential cause behind an increase in adolescents being hospitalized with the virus in March and April.  “It’s concerning, the trends on hospitalizations” among teenagers, said Gottlieb, the former Food and Drug Administration chief during the Trump administration. “I think it’s a… Read More »